

Oncology Today with Dr Neil Love: Adjuvant Therapy for ER-Positive Breast Cancer (Presentation Video)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements is true regarding the monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative early breast cancer?
  - a. Eligible patients were at high risk of recurrence
  - b. No improvement was reported in invasive disease-free survival with abemaciclib
2. The Phase III PALLAS trial evaluating the addition of palbociclib to adjuvant endocrine therapy demonstrated which of the following outcomes in the primary endpoint of invasive disease-free survival on the palbociclib arm?
  - a. A significant improvement in invasive disease-free survival
  - b. No significant improvement in invasive disease-free survival
3. Which of the following statements is FALSE regarding the diarrhea associated with the CDK4/6 inhibitor abemaciclib?
  - a. It occurs early in the course of treatment
  - b. It can be managed with loperamide and dose reductions
  - c. It usually requires permanent discontinuation of the drug
4. What was the duration of adjuvant palbociclib therapy on the Phase III PENELOPE-B trial evaluating the addition of adjuvant palbociclib to standard endocrine therapy for women with ER-positive, HER2-negative early breast cancer and residual invasive disease after completing neoadjuvant chemotherapy?
  - a. Six months
  - b. One year
  - c. Two years